FORTE Healthcare (UK) Limited announces launch of UTERTAB 2000mg, a new prescription Intrauterine Drug for the treatment and prevention of post parturient disorders in cattle.

March 2019 – UK Only

 

FORTE Healthcare (UK) Limited announces launch of UTERTAB 2000mg, a new prescription Intrauterine Drug for the treatment and prevention of post parturient disorders in cattle.

 

UTERTAB’s intrauterine administration allows it to act directly in the target tissue, and it is presented in a perforated blister pack for better sealing. Each intrauterine tablet contains active substance Tetracycline hydrochloride 2000mg.

 

Dr John Henderson, Large Animal Product Manager at Forte Healthcare Ltd said; “Given the need to use appropriate first-line antibacterial drugs where possible we are delighted to bring vets a new Tetracycline pessary, ‘Utertab’, for the treatment of metritis and retained foetal membranes.  ‘In-situ’ therapy for these conditions has more recently been neglected in favour of injectables but still has much to recommend it. We look forward to highlighting these benefits over the next few months.”

 

For further information on UTERTAB 2000mg, contact your local Forte Territory Manager or enquiries@fortehealthcare.com.

 

Ends

 

Further information available in the SPC or from Forte Healthcare Ltd. Further information available from Forte Healthcare Ltd., Block 3, Unit 9, CityNorth Business Campus, Stamullen, Co. Meath, K32 D990, Ireland. Tel: 00353 (0) 1 841 7666. Email: vets@fortehealthcare.com (technical enquiries) or enquiries@fortehealthcare.com (all other queries). Date of preparation: March 2019. FOR092.